Efficacy and safety of a combination of platelet-rich plasma with non-crosslinked hyaluronic acid versus a crosslinked hyaluronic acid, in single-injection for knee osteoarthritis. Randomized, controlled, multicenter, non-inferiority trial.

BMC Musculoskelet Disord · 2026 · PMC13041446 · PMID 41735950

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

at the limit of significancep = 0.06so close (0.05 < p ≤ 0.1)

In multivariate analysis, the only prognostic factor associated with PASS at the limit of significance was the treatment allocated at inclusion, i.e. the use of PRP-HA (OR = 2.05 [1.07–3.92]; p = 0.06).

also in 326 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.